New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market
PatentVest (MDBH) released a PatentVest Pulse report on Oct. 28, 2025 titled “The State of Cardiac Technology: The Path to Total Cardiac Intelligence.” The report sizes the opportunity as a $133 billion global cardiac diagnostics market and maps IP driving the shift from hospital-bound 12-lead ECGs to portable, connected systems.
Key facts: PatentVest captured 581 patent families across 243 organizations. The report highlights consumer wearables (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) focused on single-lead ECGs, and names innovators (HeartBeam, iRhythm, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., Bodyfriend Co.). HeartBeam is cited as the first to a cable-free 12-lead ECG replication.
PatentVest (MDBH) ha pubblicato un rapporto PatentVest Pulse il 28 ottobre 2025 intitolato “Lo stato della tecnologia cardiaca: la via verso una totalità di intelligenza cardiaca.” Il rapporto stima l'opportunità in un mercato globale di diagnostica cardiaca di $133 miliardi e traccia l'IP che guida lo spostamento dagli ECG a 12 derivazioni legati all'ospedale verso sistemi portatili e connessi.
Fatti chiave: PatentVest ha intercettato 581 famiglie di brevetti in 243 organizzazioni. Il rapporto evidenzia i dispositivi indossabili consumer (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) focalizzati su ECG a singola derivazione, e nomina innovatori (HeartBeam, iRhythm, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., Bodyfriend Co.). HeartBeam è citata come la prima a replicare un ECG a 12 derivazioni senza cavo.
PatentVest (MDBH) lanzó un informe PatentVest Pulse el 28 de oct. de 2025 titulado “El estado de la tecnología cardíaca: el camino hacia la inteligencia cardíaca total.” El informe cifra la oportunidad en un mercado global de diagnóstico cardíaco de $133 mil millones y describe las patentes que impulsan el cambio desde los ECG de 12 derivaciones hospitalarios hacia sistemas portátiles y conectados.
Datos clave: PatentVest capturó 581 familias de patentes en 243 organizaciones. El informe destaca wearables de consumo (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) centrados en ECG de una sola derivación, y nombra innovadores (HeartBeam, iRhythm, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., Bodyfriend Co.). HeartBeam se cita como el primero en replicar un ECG de 12 derivaciones sin cables.
PatentVest (MDBH)는 2025년 10월 28일 “심장 기술의 현황: 총 심장 지능으로 가는 길.”이라는 제목의 PatentVest Pulse 보고서를 발표했다. 보고서에서 기회 규모를 전 세계 심장 진단 시장의 1330억 달러로 제시하고, 12-리드 ECG가 병원 중심이던 것에서 휴대형·연결된 시스템으로의 전환을 이끄는 IP를 나타낸다.
주요 사실: PatentVest는 581개 특허 가족, 243개 기관을 포착했다. 보고서는 단일 리드 ECG에 초점을 맞춘 소비자 웨어러블(Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo)을 강조하고, 혁신가로
PatentVest (MDBH) a publié le rapport PatentVest Pulse le 28 octobre 2025 intitulé “L'état de la technologie cardiaque : le chemin vers une intelligence cardiaque totale.” Le rapport évalue l'opportunité à un marché mondial du diagnostic cardiaque de $133 milliards et décrit les brevets qui tirent le changement des ECG à 12 dérivations hospitaliers vers des systèmes portables et connectés.
Faits clés : PatentVest a capté 581 familles de brevets dans 243 organisations. Le rapport met en avant les wearables grand public (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) axés sur les ECG à une seule dérivation, et nomme les innovateurs (HeartBeam, iRhythm, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., Bodyfriend Co.). HeartBeam est cité comme le premier à reproduire un ECG à 12 dérivations sans câble.
PatentVest (MDBH) veröffentlichte am 28. Oktober 2025 einen PatentVest Pulse-Bericht mit dem Titel „Der Zustand der Herztechnologie: Der Weg zur vollständigen kardialen Intelligenz.” Der Bericht schätzt die Chance auf einen globalen Markt für kardiologische Diagnostik von $133 Milliarden und skizziert IP, die den Wandel von hospitalisierten 12-Lead-EKGs zu tragbaren, vernetzten Systemen antreibt.
Schlüsselzahlen: PatentVest hat 581 Patentfamilien über 243 Organisationen hinweg erfasst. Der Bericht hebt Verbraucher-Wearables (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) hervor, die sich auf Ein-Leged ECGs konzentrieren, und nennt Innovatoren (HeartBeam, iRhythm, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., Bodyfriend Co.). HeartBeam wird als erster zitiert, der ein kabelloses 12-Lead-ECG-Replikat erstellt hat.
PatentVest (MDBH) أصدرت تقرير PatentVest Pulse في 28 أكتوبر 2025 بعنوان “حالة تكنولوجيا القلب: الطريق إلى الذكاء القلبي الشامل.” يقدّر التقرير الفرصة بسوق تشخيص قلب عالمي قيمته $133 مليار ويرسم خريطة الملكية الفكرية الدافعة للتحول من تخطيط القلب بــ12 تخطيطاً إلى أنظمة محمولة ومتصلة.
حقائق رئيسية: سجلت PatentVest 581 عائلة براءات اختراع عبر 243 منظمة. يسلّط التقرير الضوء على أجهزة الواقع القابلة للارتداء للمستهلكين (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) مركّزاً على تخطيط القلب أحادي القناة، ويذكر مبتكرين (HeartBeam, iRhythm, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., Bodyfriend Co.). HeartBeam تُشار كأول من استنسخ تخطيط قلب بــ12 قناة دون كابل.
PatentVest (MDBH) 于 2025 年 10 月 28 日发布了一份名为 “心脏技术的现况：通往全面心脏智能的路径。” 的 PatentVest Pulse 报告。该报告将全球心脏诊断市场的机会估计为 $1330 亿，并绘制了推动从医院束缚的 12 导联心电图向便携、连接系统转变的知识产权路径。
关键事实：PatentVest 捕获了 581 个专利族，覆盖 243 家机构。报告强调以单导联心电图为重点的消费级可穿戴设备（Apple、Samsung、Google/Fitbit、Whoop、Oura、Withings、Garmin、Zepp Health、Masimo），并点名创新者（HeartBeam、iRhythm、AliveCor、Mayo Clinic、Tempus AI、Eko Health、Anumana、Medical AI Co.、Bodyfriend Co.）。HeartBeam 被引用为首个无电缆实现 12 导联心电图复制的案例。
- $133B global cardiac diagnostics market opportunity
- PatentVest captured 581 patent families across 243 organizations
- HeartBeam cited as first to a cable-free 12-lead ECG
- Emerging companies (AliveCor, iRhythm, HeartBeam) challenge incumbents
- Consumer single-lead ECGs cannot detect ischemia
- IP activity concentrates on single-lead rhythm screening, not full diagnostic capability
Insights
Patent landscape report highlights who controls IP in a growing
The analysis maps 581 patent families across 243 organizations and contrasts established medical-device incumbents such as Philips, GE Healthcare, and Nihon Kohden with newer entrants like HeartBeam, AliveCor, Mayo Clinic, and others. The report frames the shift from hospital‑confined 12‑lead ECGs to portable and consumer systems and identifies IP ownership as a central competitive lever.
Key dependencies and risks include the degree to which consumer wearables (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) remain limited to single‑lead rhythm screening versus development of full diagnostic capability, and whether ambulatory innovators (for example HeartBeam, described as offering cable‑free 12‑lead ECG) can translate patent positions into validated, marketable devices. The report's raw metrics (581 patent families, 243 organizations) are concrete signals of activity but do not by themselves prove commercial leadership.
Concrete items to watch are continued patent filings and enforcement activity by the named firms, any regulatory clearances tied to diagnostic accuracy claims, and product rollouts that aim to replicate hospital 12‑lead performance; track these near term from the report date
Designed for investors, board members, and CEOs, the latest PatentVest Pulse report offers a strategic view of who’s leading and why in the rapidly evolving cardiac diagnostics market
Dallas, TX, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The State of Cardiac Technology: The Path to Total Cardiac Intelligence.”
The report shows how the convergence of consumer technology, ambulatory monitoring, and traditional medical systems is redefining the future of cardiac care, and how control over intellectual property will determine which companies lead the next era of diagnostics.
Cardiovascular disease remains the world’s leading cause of death, responsible for one in four U.S. fatalities. Yet the diagnostic gold standard, the 12-lead electrocardiogram (ECG), has remained largely confined to hospitals for nearly a century. Now, a
Key Insights
- Consumer Wearables: Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, and Masimo have brought heart rate racking and single-lead ECGs to hundreds of millions of wrists. Yet these implementations remain confined to rhythm screening unable to detect ischemia or replicate 12-lead diagnostic accuracy. IP activity across these companies centers on single-lead ECG for heart rate and basic arrhythmia detection rather than full diagnostic capability.
- Ambulatory Monitoring: Companies such as HeartBeam, iRhythm, and AliveCor are developing portable systems that move beyond rhythm tracking toward diagnostic-grade performance. HeartBeam emerges as the first to cable-free 12L ECG, replicating the gold standard.
- IP Landscape: PatentVest’s captured 581 patent families across 243 organizations using our proprietary Global IP database which show that traditional device makers like Philips, GE Healthcare, and Nihon Kohden are being challenged by emerging innovators including HeartBeam, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., and Bodyfriend Co.
“Cardiac diagnostics have been trapped inside hospitals for nearly a century,” said Javier Chamorro, Chief Operating Officer. “As consumer and medtech companies push toward real-time, hospital-grade monitoring beyond the clinic, the decisive factor is who owns the enabling IP.”
About the Report:
The analysis benchmarks the technologies, product offerings, and patent portfolios of the leading consumer, medtech innovators, and medical device companies - including Apple, Samsung, Google/Fitbit, Oura, Whoop, Withings, Garmin, Zepp Health, Masimo, HeartBeam, iRhythm, AliveCor, Philips, GE Healthcare, Nihon Kohden, and Schiller AG, alongside a comprehensive mapping of 581 patent families across 243 organizations. The report highlights who is closest to replicating the diagnostic gold standard, and who owns the intellectual property shaping the next era of cardiac care.
Access the Full Report
This new PatentVest Pulse report is now available. Get the data, insights, and strategic intelligence behind the companies shaping the future of cardiac health: Read the full report here.
For more information or inquiries, please contact info@patentvest.com.
About PatentVest
PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. By combining a proprietary database with a proven diligence process and expert analysis, PatentVest delivers actionable insights that help clients navigate complex IP landscapes and stay ahead of the curve. This report is powered by PatentVest’s proprietary IP intelligence platform.
FAQ
What did PatentVest announce about the cardiac diagnostics market on Oct. 28, 2025 for MDBH?
How many patent families and organizations does PatentVest report for cardiac technology (MDBH)?
What limitation does the report identify for consumer wearables such as Apple and Fitbit (MDBH report)?
Which companies does the PatentVest Pulse report highlight as emerging diagnostic innovators (MDBH)?
What IP advantage does the report say will determine leadership in cardiac diagnostics (MDBH)?
